As summarized in Figure 6, our results suggest that CD163+ monocyte-mediated T cell activation was down-regulated in individuals with diabetes-related complications, due to the increased CD5 and decreased CD86 expression. This evidence concerns the gene CD86 and diabetes mellitus.